PSG Wealth Creator Fund of Funds B (PACB) Jumps 9.43% on February 22

Equities Staff |

PSG Wealth Creator Fund of Funds B (PACB) was among the biggest gainers on the Russell 2000 for Monday February 22 as the stock popped 9.43% to $8.82, representing a gain of $0.76 per share. Some 1.7 million shares traded hands on 8,020 trades, compared with an average daily volume of 2.25 million shares out of a total float of 77.04 million. The stock opened at $8.06 and traded with an intraday range of $9.08 to $8.06.

After today's gains, PSG Wealth Creator Fund of Funds B reached a market cap of $679.5 million. PSG Wealth Creator Fund of Funds B has had a trading range between $14.00 and $3.58 over the last year, and it had a 50-day SMA of $11.21 and a 200-day SMA of $7.38.

Pacific Biosciences of California Inc is engaged in design, development and manufacture of sequencing system to help scientists resolve genetically complex problems.

PSG Wealth Creator Fund of Funds B is based out of Menlo Park, CA and has some 344 employees. Its CEO is Michael Hunkapiller.

For a complete fundamental analysis analysis of PSG Wealth Creator Fund of Funds B, check out’s Stock Valuation Analysis report for PACB. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


Autonomous security robots providing advanced detection capabilities at $7 per hour - aiming to define the future of security. Help #StopTheViolence.


Blockchain currencies (e.g. Bitcoin) provide a new disruptive way to transfer value between parties over the internet as opposed to going through banks. GoCoin provides online merchants with a suite…